Startups
CARDIODX is a molecular diagnostics company that serves cardiologists and their patients by offering clinically validated genomic tests to enhance patient care. The company is focused on the personalized management of patients with congestive heart failure, rhythm disturbances and atherosclerosis.
Overview
Location
United States, California, Redwood City
Employees
51-200
Total raised
$123M
Founded date
2004
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 11, 2011 | Funding round | $60M | |
| May 14, 2010 | Funding round | $5M |
Mentions in press and media 20
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 5, 2015 | Stanford Health Care and GE Ventures form new company to validate and optimize digital health technology | To illustrate the growth of digital health tools, a Rock Health report released earlier this year said more than $4 billion in venture funding was invested in over 250 digital health companies in 2014 alone. Evidation raised $6.2 million in... |
| Nov 21, 2013 | With 5 postponed public offerings this month, is the IPO window beginning to close for biotechs? | Biotechnology companies have been a big source of IPOs this year. There have been 50 healthcare IPOs to date that have raised more than $8 billion, the most of any industry, according to data from Renaissance Capital’s IPO Center. On the ot... |
| Nov 6, 2013 | CardioDx aims for $92M IPO | California molecular diagnostics company CardioDx unveiled new details of its initial public offering, slated to raise $92 million through shares priced at $14-$16 apiece. Once the IPO launches, CardioDx will trade on the Nasdaq stock marke... |
| Jul 11, 2013 | Unmet need, actionable results, clinical utility: 3 non-negotiables for new diagnostics | There are thousands of genetic test products on the market today, and more being introduced all the time. As targeted drugs and personalized medicine become reality, the diagnostics market has become a welcoming place for startups. That doe... |
| Nov 16, 2012 | 8 things pharmaceutical companies can do to ensure their survival | Develop better reward system It would be better for drug companies to use a measurement system that combines financial and non-financial metrics (like motivation and commitment), the report notes. That system should also be flexible enough ... |
| Aug 27, 2012 | CardioDx Completes $58M Equity Financing | PALO ALTO, CA, Pioneer in the field of cardiovascular genomic diagnostics, today announced the completion of a $58 million two-tranche equity financing. >> Click here for more funding data on CardioDx >> To export CardioDx f... |
| Aug 27, 2012 | CardioDx Completes $58M Equity Financing | CardioDx, Inc., a Palo Alto, CA-based developer of cardiovascular genomic diagnostic solutions, has completed a $58m two-tranche equity financing. Backers include Temasek and existing investors Longitude Capital, Artiman Ventures, Kleiner, ... |
| May 15, 2012 | GE $250M fund manager: We have a lot of dry powder, looking to invest | How much of the $250 million have you invested? For competitive reasons, we don’t disclose that, but we have a lot of dry powder. We’re more opportunity short than capital short, which is a great place to be in in this environment given som... |
| Apr 2, 2012 | What venture capitalists look for in personalized medicine investments | “Because they can offer the right product, they can take away unnecessary costs,” Kocher said. “And in healthcare, that’s what we really need to do.” Personalized medicine will help doctors determine what to treat, how to treat and how much... |
Show more
Reviews 0
FAQ about CardioDx
When was CardioDx founded?
CardioDx was founded in 2004.
How much funding has CardioDx raised?
CardioDx has raised $123M in total across 3 funding rounds.
What funding rounds has CardioDx raised?
Parsers VC lists 3 funding rounds of CardioDx, among them a funding round of $60M on May 11, 2011 and a funding round of $5M on May 14, 2010.
What has the press written about CardioDx?
Parsers VC has collected 20 articles mentioning CardioDx, among them “Stanford Health Care and GE Ventures form new company to validate and optimize digital health technology” (Mar 5, 2015) and “With 5 postponed public offerings this month, is the IPO window beginning to close for biotechs?” (Nov 21, 2013).
Is CardioDx still active?
CardioDx is probably closed: its latest activity on Parsers VC dates from Sep 20, 2018.